Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77230-1402, USA.
Endocr Pract. 2009 Sep-Oct;15(6):605-11. doi: 10.4158/EP09131.RAR.
To review the emerging evidence that therapies targeting key oncogenic and signaling kinases can be effective in treatment of advanced thyroid carcinomas.
With use of PubMed and Google Scholar, a systematic review was performed of publications and scientific presentations summarizing pertinent clinical trials.
Studies of numerous inhibitors of BRAF, vascular endothelial growth factor receptor, and RET kinases indicate that patients with progressive or metastatic thyroid carcinoma can benefit from therapy with these novel agents. Severe toxic effects, however, are associated with these treatments, and caution is recommended in their use.
Further trials and identification of improved therapeutic targeting should lead to development of more effective treatments of thyroid carcinomas.
回顾靶向关键致癌和信号激酶的治疗方法在治疗晚期甲状腺癌方面可能具有疗效的新证据。
使用 PubMed 和 Google Scholar，对总结相关临床试验的出版物和科学报告进行了系统综述。
针对 BRAF、血管内皮生长因子受体和 RET 激酶的多种抑制剂的研究表明，患有进行性或转移性甲状腺癌的患者可以从这些新型药物的治疗中获益。然而，这些治疗方法会引起严重的毒性反应，因此在使用时需要谨慎。
进一步的试验和改进的治疗靶点的确定应能导致开发出更有效的甲状腺癌治疗方法。
Zotero 插件